CFAP221

Across TCGA pan-cancer cohorts, CFAP221 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CFAP221 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CFAP221 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP221 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LIHC, BLCA, and UCEC are the cancer types where CFAP221 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.047	0.783	<.001	12	view →
BLCA	OS	Median	IV	1.000	0.301	.007	9	view →
UCEC	DFS	Median	All	0.917	0.626	.021	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CFAP221–LIHC (OS)

Open the LIHC breakdown →